REG - Avacta Group PLC - R&D Spotlight focusing on pipeline advances

AvactaAnnouncement

30/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241030:nRSd1323Ka&default-theme=true

RNS Number : 1323K  Avacta Group PLC  30 October 2024

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

R&D Spotlight focusing on pre|CISION(®) technology and pipeline advances

 

LONDON - Oct. 30, 2024 - Avacta Therapeutics (AIM: AVCT), a life sciences
company developing next generation peptide drug conjugates (PDC) targeting
powerful antitumor payloads directly to the tumor, is today hosting a live
R&D Spotlight: "Next Generation of pre|CISION(®) Medicines" in London.

 

Avacta's unique proprietary technology allows for targeted delivery of
cytotoxic drugs (the "payload") in the tumor microenvironment (TME). The
presentations will cover the Company's next generation of follow-on candidates
with their unique features and patient populations.

 

Avacta will highlight in this event the novel pre|CISION(®) candidates in the
evolving pipeline, details of which were presented at the EORTC-NCI-AACR
Triple Meeting in Barcelona last week and provide further detail on their
properties and patient populations.

 

Avacta's AVA6000, AVA6103, and AVA7100 programs are highly differentiated
pipeline assets, addressing large markets. The presentation will also address
these programs' near-term milestones.

 

Avacta will highlight the franchise it has developed in breast cancer and how
these therapies in this indication will move forward.

 

The Company confirms that the process to divest the revenue-generating
diagnostics division is ongoing and it continues to actively explore
opportunities for a potential dual listing on NASDAQ. No additional financial
information will be disclosed.

 

This event is open to both analysts and investors, further details are
provided on the Company website and a recording of the event will be made
available in due course.

 

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc

 Michael Vinegrad, Group Communications Director       https://avacta.com/ (https://avacta.com/)
                                                       www.peelhunt.com (http://www.peelhunt.com)

 Peel Hunt (Nomad and Broker)

 James Steel / Chris Golden / Patrick Birkholm

 ICR Healthcare                                        avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

About the pre|CISION(®) Platform

 

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

About AVA6000: FAP-enabled doxorubicin

 

The lead pre|CISION(®) program AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple patients. To register for
news alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

AVA6103: FAP-enabled PDC targeting Topoisomerase I

AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked
to exatecan, the most potent topoisomerase I inhibitor in clinical
development. Exatecan has demonstrated clinical activity in breast, gastric,
lung and pancreatic cancers; however, it is associated with severe
dose-limiting toxicities and a short half-life in patients that led to
discontinuation of its monotherapy development. AVA6103 is designed to enable
patients to obtain the therapeutic benefit associated with exatecan, while
limiting the systemic exposure associated with its poor tolerability.

 

 

AVA7100: pre|CISION(®) FAP Affimer Drug Conjugate (AffDC)

 

AVA7100 is a pre|CISION(®)-enabled Affimer(®) drug conjugate, a new class
of therapies being developed by Avacta with potential applications in a
variety of cancer types, including those with lower levels of FAP in the
tumor. Affimer(® )molecules are small proteins that are engineered to bind
to a target molecule in the same way that an antibody does, but with several
advantages, including smaller molecule size and a broad range of binding
affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a
pre|CISION(®)-peptide linker with multiple options for the payload.

 

About Avacta Group plc - https://avacta.com/ (https://avacta.com/)

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics. Its
clinical stage oncology biotech division Avacta Therapeutics is harnessing the
proprietary pre|CISION(®) platform technology to develop novel, highly
targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare
professionals and broadening access to diagnostics. To register for news
alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAAENAENLFAA